Tuomas R. Holmberg
Fondatore presso NovaDigm Therapeutics, Inc.
Posizioni attive di Tuomas R. Holmberg
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
NovaDigm Therapeutics, Inc.
 NovaDigm Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology NovaDigm Therapeutics, Inc. developes innovative immunotherapeutics and preventative vaccines. It protect patients from fungal and bacterial infections, which can be recurrent, drug-resistant and in some cases, life-threatening. The firm NDV-3A, is the first vaccine to demonstrate preclinical efficacy in reducing the severity of disease caused by both fungal and bacterial pathogens. NDV-3A is in Phase 2 clinical development for recurrent vulvovaginal candidiasis (RVVC) with follow-on indications planned for Candida, a fungal pathogen, and Staphylococcus aureus, including MRSA. The company was founded by Toumas R. Holmberg, Michael R. Yeaman, Frederick M.Haneyand John E. Eswards Jr. in 2005 and is headquartered in Grand Forks ND. | Direttore/Membro del Consiglio | 01/01/2005 | - |
| Fondatore | 01/01/2005 | - | |
| Corporate Officer/Principal | 01/01/2005 | - |
Storia della carriera di Tuomas R. Holmberg
Precedenti posizioni note di Tuomas R. Holmberg
| Società | Posizione | Inizio | Fine |
|---|
Formazione di Tuomas R. Holmberg
| University of Southern California | Masters Business Admin |
| California Institute of Technology | Undergraduate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 4 |
Posizioni
| Founder | 2 |
| Director/Board Member | 1 |
| Corporate Officer/Principal | 1 |
Settori
| Consumer Services | 3 |
| Health Technology | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Aziende private | 1 |
|---|---|
NovaDigm Therapeutics, Inc.
NovaDigm Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology NovaDigm Therapeutics, Inc. developes innovative immunotherapeutics and preventative vaccines. It protect patients from fungal and bacterial infections, which can be recurrent, drug-resistant and in some cases, life-threatening. The firm NDV-3A, is the first vaccine to demonstrate preclinical efficacy in reducing the severity of disease caused by both fungal and bacterial pathogens. NDV-3A is in Phase 2 clinical development for recurrent vulvovaginal candidiasis (RVVC) with follow-on indications planned for Candida, a fungal pathogen, and Staphylococcus aureus, including MRSA. The company was founded by Toumas R. Holmberg, Michael R. Yeaman, Frederick M.Haneyand John E. Eswards Jr. in 2005 and is headquartered in Grand Forks ND. | Health Technology |
- Borsa valori
- Insiders
- Tuomas R. Holmberg
- Esperienza
